{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:52:17Z","timestamp":1779205937103,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ejim.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:26:42Z","timestamp":1707467202000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-6505","authenticated-orcid":false,"given":"Kunal","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3774-4184","authenticated-orcid":false,"given":"Anil","family":"Dhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.02.004_bib0001","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"73","key":"10.1016\/j.ejim.2024.02.004_bib0003","first-page":"e285","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol","volume":"2019","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries. Findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2024.02.004_bib0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2024.02.004_bib0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40256-019-00379-9","article-title":"Lipid-lowering efficacy of ezetimibe in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analyses","volume":"20","author":"Shaya","year":"2020","journal-title":"Am J Cardiovasc Drug"},{"key":"10.1016\/j.ejim.2024.02.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ihj.2023.09.005","article-title":"Impact of early initiation of proprotein convertase subtilisin\/kexin type 9 inhibitors in patients with acute coronary syndrome: a systematic review meta-analysis","author":"Nagendra","year":"2023","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ejim.2024.02.004_bib0008","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT investigators. ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.02.004_bib0009","article-title":"Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes","volume":"14","author":"Li","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ejim.2024.02.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2995602","article-title":"Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","article-title":"A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin","volume":"235","author":"Ran","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0012","first-page":"4942","article-title":"Comparison of the effect of rosuvastatin versus rosuvastatin\/ezetimibe on markers of inflammation in patients with acute myocardial infarction","volume":"14","author":"Ren","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ejim.2024.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.10.083","article-title":"The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients","volume":"242","author":"Lin","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.21037\/jtd.2017.05.46","article-title":"Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention","volume":"9","author":"Dai","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejim.2024.02.004_bib0015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1253\/circj.CJ-17-0598","article-title":"Ezetimibe-ACS investigators. Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome","volume":"82","author":"Hibi","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.02.004_bib0016","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.02.004_bib0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FJC.0b013e31821e8cb2","article-title":"Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events","volume":"58","author":"Undas","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/109158","article-title":"Effects of statin versus the combination of ezetimibe plus statin on serum lipid absorption markers in patients with acute coronary syndrome","volume":"2015","author":"Watanabe","year":"2015","journal-title":"J Lipids"},{"key":"10.1016\/j.ejim.2024.02.004_bib0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jacl.2022.03.008","article-title":"Evidence for intensive LDL-C lowering for acute coronary syndrome: recommendations from the Lipid Association of India","volume":"16","author":"Puri","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: a meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.ejim.2024.02.004_bib0021","article-title":"Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis","volume":"17","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ejim.2024.02.004_bib0022","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.02.004_bib0023","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.02.004_bib0024","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.ejim.2024.02.004_bib0025","first-page":"1","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess (Rockv)"},{"key":"10.1016\/j.ejim.2024.02.004_bib0026","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1253\/circj.CJ-17-0193","article-title":"Effect of ezetimibe on stabilization and regression of intracoronary plaque - the ZIPANGU study","volume":"81","author":"Ueda","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2024.02.004_bib0027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hlc.2015.10.012","article-title":"Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease","volume":"25","author":"Wang","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.ejim.2024.02.004_bib0028","doi-asserted-by":"crossref","first-page":"770","DOI":"10.5603\/KP.a2017.0074","article-title":"The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender","volume":"75","author":"Japaridze","year":"2017","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.ejim.2024.02.004_bib0029","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s12325-021-01741-7","article-title":"Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome","volume":"38","author":"Tan","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2024.02.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9815016","article-title":"Ezetimibe and improving cardiovascular outcomes: current evidence and perspectives","volume":"2020","author":"Pradhan","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.ejim.2024.02.004_bib0031","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ejim.2024.02.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2024.02.004_bib0033","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.02.004_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ejim.2024.02.004_bib0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3904\/kjim.2023.243","article-title":"Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia","volume":"38","author":"Lee","year":"2023","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2024.02.004_bib0036","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1017\/S0266462323000296","article-title":"Cost-effectiveness of adding ezetimibe and\/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults","volume":"39","author":"Xiang","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ejim.2024.02.004_bib0037","doi-asserted-by":"crossref","first-page":"244","DOI":"10.23736\/S0031-0808.22.04777-2","article-title":"Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice","volume":"65","author":"Sabouret","year":"2023","journal-title":"Panminerva Med"},{"issue":"18","key":"10.1016\/j.ejim.2024.02.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031615","article-title":"Upfront combination of statin and ezetimibe for patients with acute coronary syndrome: time for a new approach?","volume":"12","author":"Ya'Qoub","year":"2023","journal-title":"J Am Heart Assoc"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T15:38:20Z","timestamp":1717515500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"alternative-id":["S0953620524000499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.02.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}